Therapeutic drug monitoring of clozapine and olanzapine. Similarities and differences;Therapeutisches drug-monitoring von clozapin und olanzapin. Ahnlichkeiten und unterschiede

Psychopharmakotherapie

Volumn 6, Issue 3, 1999, Pages 105-109

  Gaertner, I ^a   Gaertner, H J ^a   Lampe, D ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Berliner Betrieb F Zentrale G   (Germany)

Author keywords

Clozapine; Drug interactions; Fluvoxamine; Olanzapine; Patient variables; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; DIAZEPAM; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; METOPROLOL; NORCLOZAPINE; OLANZAPINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0032798472     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, et al. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1992;45:1211-4.
2. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994;14:119-25
3. Dahl ML, Llerena A, Bonderson U, Lindström L, et al. Disposition of clozapine in man: Lack of association with debrisoquin and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994;37:71-4.
4. Haring C, Fleischhacker WW, Schett, P, Humpel C, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-5.
5. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
6. Jerling M, Leif B, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
7. Kronig MH, Munne RA, Szymanski S, Safferman AZ, et al. Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am J Psychiatry 1995;152: 179-82.
8. Meltzer HY. Atypical antipsychotic drug therapy for treatment-resistant schizophrenia. In: Hirsch SR, Weinberger DR, editors. Oxford: Blackwell Science Ltd., 1995:485-502.
9. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl B): 117-21.
10. Owen JA, Delva NJ, Lawson JS. Clozapine concentrations and clinical response in schizophrenic patients [letter, comment]. Am J Psychiatry 1992;149:1120-1.
11. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 1991;148:231-5; erratum: 1427.
12. Perry PJ, Smith DA. Neuroleptic plasma concentrations. An estimate of their sensitivity and specifity as a predictor of response. In: Marder SR, Davis JM, Janicak PG, editors. Clinical Use of Neuroleptic Plasmalevels. Washington: American Psychiatric Press, 1993:113-35.
13. Piscitelli SC, Frazier JA, Mc Kenna K, Albus KE, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood onset schizophrenia: association with response. J Clin Psychiatry 1994;55(Suppl B):94-7.
14. Potkin SG, Bera R, Gulasekaram B, Costa J, et al. Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl B): 133-6.
15. Raitasuo V, Lehtovaara R, Huttuner M. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993;150:169.
16. Shroder S, Calabrese P. Clozapine plasma levels. Pharmacopsychiatry 1995;28:214.
17. Stevens I, Mahal A, Gaertner HJ. Clozapin-Plasmaspiegel bei der Akuttherapie von schizophrenen Patienten. Psychopharmakotherapie 1995;2:77-81
18. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasmalevels of neuroleptics. Pharmacopsychiatry 1994;28:26-8.
19. Hirsch S, Weinberger DR. Schizophrenia. Osvord: Blackwell Science, 1995.